Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Regeneron

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Regeneron's Japan sales performance.

regeneron

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Esperion gets FDA thumbs up for cholesterol drug Nexletol

and Sanofi/Regeneron – and could see a launch later this year for Novartis’ PCSK9 drug  inclisiran. ... Sanofi/Regeneron’s Praluent (alirocumab), which have both failed to live up to initial blockbuster sales predictions.

Immutep spikes on trial of its LAG-3 drug with Keytruda

Immutep spikes on trial of its LAG-3 drug with Keytruda Regeneron, which all have candidates in clinical development.

Incyte’s JAK inhibitor cream clears second eczema trial

Incyte’s JAK inhibitor cream clears second eczema trial So if approved, ruxolitinib cream would address a less severely-affected population than new biologic agents such as Sanofi/Regeneron’s blockbuster  Dupixent (dupilumab) antibody.

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD Beovu represents Novartis’ attempt to defend its wet AMD franchise as Lucentis starts to decline, squeezed by Eylea – which is also sold by Regeneron – as well as off-label use of ... Roche – which sells Lucentis in the US – made $1.83bn from

Revenue growth at Ipsen numbs pain of palovarotene calamity

Revenue growth at Ipsen numbs pain of palovarotene calamity Rival candidates for FOP are however coming through the pipeline, including Regeneron’s antibody garetosmab that generated positive phase 2 results in the disease last month, including a 90% reduction in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics